JP2020506943A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020506943A5 JP2020506943A5 JP2019542453A JP2019542453A JP2020506943A5 JP 2020506943 A5 JP2020506943 A5 JP 2020506943A5 JP 2019542453 A JP2019542453 A JP 2019542453A JP 2019542453 A JP2019542453 A JP 2019542453A JP 2020506943 A5 JP2020506943 A5 JP 2020506943A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- combination
- pharmaceutical composition
- antigen
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108700028369 Alleles Proteins 0.000 claims description 107
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 86
- 238000000034 method Methods 0.000 claims description 77
- 239000000427 antigen Substances 0.000 claims description 70
- 108091007433 antigens Proteins 0.000 claims description 70
- 102000036639 antigens Human genes 0.000 claims description 70
- 239000008194 pharmaceutical composition Substances 0.000 claims description 55
- 230000000694 effects Effects 0.000 claims description 49
- 244000052769 pathogen Species 0.000 claims description 35
- 230000001717 pathogenic effect Effects 0.000 claims description 34
- 206010028980 Neoplasm Diseases 0.000 claims description 29
- 201000011510 cancer Diseases 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 29
- 230000002401 inhibitory effect Effects 0.000 claims description 27
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims description 25
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims description 25
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims description 25
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims description 25
- 239000012190 activator Substances 0.000 claims description 17
- 230000001225 therapeutic effect Effects 0.000 claims description 16
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 15
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 230000004936 stimulating effect Effects 0.000 claims description 13
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 12
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 12
- 210000005260 human cell Anatomy 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 7
- 102100038078 CD276 antigen Human genes 0.000 claims description 6
- 101710185679 CD276 antigen Proteins 0.000 claims description 6
- 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 claims description 6
- 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 claims description 6
- 102000002698 KIR Receptors Human genes 0.000 claims description 6
- 108010043610 KIR Receptors Proteins 0.000 claims description 6
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims description 6
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 claims description 6
- 108010079206 V-Set Domain-Containing T-Cell Activation Inhibitor 1 Proteins 0.000 claims description 6
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims description 6
- 230000000735 allogeneic effect Effects 0.000 claims description 6
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 claims description 6
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 claims description 6
- 239000003446 ligand Substances 0.000 claims description 6
- 241000701022 Cytomegalovirus Species 0.000 claims description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 5
- 208000008383 Wilms tumor Diseases 0.000 claims description 5
- 208000026448 Wilms tumor 1 Diseases 0.000 claims description 5
- 101710127857 Wilms tumor protein Proteins 0.000 claims description 5
- 102100022748 Wilms tumor protein Human genes 0.000 claims description 5
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 101001055145 Homo sapiens Interleukin-2 receptor subunit beta Proteins 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 4
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 4
- 102100026879 Interleukin-2 receptor subunit beta Human genes 0.000 claims description 4
- 102000017578 LAG3 Human genes 0.000 claims description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 4
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 4
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 4
- 238000003782 apoptosis assay Methods 0.000 claims description 4
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000005522 programmed cell death Effects 0.000 claims description 4
- 230000001149 cognitive effect Effects 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 102000007471 Adenosine A2A receptor Human genes 0.000 claims description 2
- 108010085277 Adenosine A2A receptor Proteins 0.000 claims description 2
- 101150051188 Adora2a gene Proteins 0.000 claims description 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims description 2
- 102000050627 Glucocorticoid-Induced TNFR-Related Human genes 0.000 claims description 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims description 2
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 230000006044 T cell activation Effects 0.000 claims description 2
- 101710187882 Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 230000004913 activation Effects 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 238000001727 in vivo Methods 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 108700021638 Neuro-Oncological Ventral Antigen Proteins 0.000 claims 2
- 241000700605 Viruses Species 0.000 description 13
- 241001529453 unidentified herpesvirus Species 0.000 description 5
- -1 BTLA Proteins 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 241000711549 Hepacivirus C Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 241000829111 Human polyomavirus 1 Species 0.000 description 3
- 241000579048 Merkel cell polyomavirus Species 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 description 2
- 241001115402 Ebolavirus Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 108010034145 Helminth Proteins Proteins 0.000 description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 description 2
- 241000700721 Hepatitis B virus Species 0.000 description 2
- 101100215487 Sus scrofa ADRA2A gene Proteins 0.000 description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 description 2
- 229960003852 atezolizumab Drugs 0.000 description 2
- 229950002916 avelumab Drugs 0.000 description 2
- 229950009791 durvalumab Drugs 0.000 description 2
- 244000000013 helminth Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 229950010773 pidilizumab Drugs 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762455860P | 2017-02-07 | 2017-02-07 | |
| US62/455,860 | 2017-02-07 | ||
| PCT/US2018/016995 WO2018148183A1 (en) | 2017-02-07 | 2018-02-06 | Use of immune checkpoint modulators in combination with antigen-specific t cells in adoptive immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020506943A JP2020506943A (ja) | 2020-03-05 |
| JP2020506943A5 true JP2020506943A5 (https=) | 2021-02-25 |
Family
ID=61274340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542453A Pending JP2020506943A (ja) | 2017-02-07 | 2018-02-06 | 養子免疫療法における抗原特異的ｔ細胞と組み合わせた免疫チェックポイント調節剤の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20200017586A1 (https=) |
| EP (1) | EP3579846A1 (https=) |
| JP (1) | JP2020506943A (https=) |
| AU (1) | AU2018218221A1 (https=) |
| CA (1) | CA3051869A1 (https=) |
| WO (1) | WO2018148183A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11162079B2 (en) | 2019-05-10 | 2021-11-02 | The Regents Of The University Of California | Blood type O Rh-hypo-immunogenic pluripotent cells |
| US12221622B2 (en) | 2019-05-10 | 2025-02-11 | The Regents Of The University Of California | Modified pluripotent cells |
| WO2021009510A1 (en) * | 2019-07-16 | 2021-01-21 | Autolus Limited | Method for preconditioning a subject who is about to receive a t-cell therapy |
| CA3247422A1 (en) * | 2022-04-13 | 2023-10-19 | The Regents Of The University Of California | IMMUNE CELL INHIBITION BY IMMUNE CHECKPOINT ENGAGERS |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101523391B1 (ko) * | 2006-12-27 | 2015-05-27 | 에모리 유니버시티 | 감염 및 종양 치료를 위한 조성물 및 방법 |
| MX2011005691A (es) * | 2008-11-28 | 2011-07-20 | Univ Emory | Metodos para el tratamiento de infecciones y tumores. |
| IL292510A (en) * | 2013-11-05 | 2022-06-01 | Cognate Bioservices Inc | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| AU2015343239B2 (en) * | 2014-11-05 | 2021-06-03 | Memorial Sloan Kettering Cancer Center | Methods of selecting T cell line and donor thereof for adoptive cellular therapy |
| WO2016145578A1 (en) * | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
| CN117467603A (zh) * | 2015-04-27 | 2024-01-30 | 癌症研究技术有限公司 | 治疗癌症的方法 |
-
2018
- 2018-02-06 JP JP2019542453A patent/JP2020506943A/ja active Pending
- 2018-02-06 US US16/483,880 patent/US20200017586A1/en not_active Abandoned
- 2018-02-06 AU AU2018218221A patent/AU2018218221A1/en not_active Abandoned
- 2018-02-06 CA CA3051869A patent/CA3051869A1/en active Pending
- 2018-02-06 WO PCT/US2018/016995 patent/WO2018148183A1/en not_active Ceased
- 2018-02-06 EP EP18707180.8A patent/EP3579846A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Scully et al. | NK cells in HIV disease | |
| Gillespie et al. | Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8+ T lymphocytes in healthy seropositive donors | |
| JP6995624B2 (ja) | 修正ガンマデルタｔ細胞およびその使用 | |
| Saglio et al. | The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care | |
| Retière et al. | Generation of cytomegalovirus-specific human T-lymphocyte clones by using autologous B-lymphoblastoid cells with stable expression of pp65 or IE1 proteins: a tool to study the fine specificity of the antiviral response | |
| Sahu et al. | Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells | |
| Bollard et al. | Adoptive immunotherapy for posttransplantation viral infections | |
| Einsele et al. | CMV-specific T cell therapy | |
| AU2017330379B2 (en) | Generation and use in adoptive immunotherapy of stem cell-like memory T cells | |
| Zelinskyy et al. | Virus-specific CD8+ T cells upregulate programmed death-1 expression during acute friend retrovirus infection but are highly cytotoxic and control virus replication | |
| US20200182884A1 (en) | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses | |
| Kaufmann et al. | Programmed death-1 as a factor in immune exhaustion and activation in HIV infection | |
| JP2020506943A5 (https=) | ||
| US20220211759A1 (en) | Modulation of expression of genes related to t cell exhaustion | |
| Piersma et al. | Natural killer cell effector functions in antiviral defense | |
| Locatelli et al. | Cytomegalovirus in hematopoietic stem cell transplant recipients-management of infection | |
| Mehdizadeh et al. | Immunotherapy with adoptive cytomegalovirus‐specific T cells transfer: Summarizing latest gene engineering techniques | |
| Molloy et al. | Suppressive CD8+ T cells arise in the absence of CD4 help and compromise control of persistent virus | |
| Scalzo et al. | Cmv1 and natural killer cell responses to murine cytomegalovirus infection | |
| US20200017586A1 (en) | Use of immune checkpoint modulators in combination with antigen-specific t cells in adoptive immunotherapy | |
| Sellar et al. | The role of virus-specific adoptive T-cell therapy in hematopoietic transplantation | |
| US20230405047A1 (en) | Methods and compositions for eliminating engineered immune cells | |
| Haveman et al. | Selection of perforin expressing CD4+ adenovirus-specific T-cells with artificial antigen presenting cells | |
| Hamel et al. | Characterization of antigen‐specific repertoire diversity following in vitro restimulation by a recombinant adenovirus expressing human cytomegalovirus pp65 | |
| George et al. | Transcriptional profiling of peripheral CD8+ T cell responses to SIVΔnef and SIVmac251 challenge reveals a link between protective immunity and induction of systemic immunoregulatory mechanisms |